Clinical and Demographic Characteristics of 508 Multiple Sclerosis Patients Using Fingolimod (Vintor) Treatment (Two-Year Efficacy and Reliability Data)
Makaleler > Tam Makale · 2022
Yazarlar: Elif Merve HELVACI, Murat TERZİ, Sedat ŞEN, Cavit BOZ, Vedat ÇİLİNGİR, Aylin AKÇALI, Yeşim BECKMANN, Cihat UZUNKÖPRÜ, Recai TÜRKOĞLU, Ayşe Nur YÜCEYAR, Hüsnü EFENDİ, Sena DESTAN BÜNÜL, Meral SEFEROĞLU, Dilcan KOTAN, Sibel GÜLER, Belgin PETEK BALCI, Bilgin ÖZTÜRK, Semra MUNGAN, Nilüfer KALE İÇEN, Sami ÖMERHOCA, Şükran YURTOĞULLARI, Serhan SEVİM, Şule AYDIN TÜRKOĞLU, Mustafa ÇAM, Mehmet Fatih YETKİN, Tahir KURTULUŞ YOLDAŞ, Ali Özhan SIVACI, Şeyda Figül GÖKÇE, Esra GÜRSOY, Aysun ÜNAL, Nuray BİLGE, Kadriye AĞAN, Münire KILINÇ TOPRAK, Belgin KOÇER, Yüksel TERZİ
Archives of Neuropsychiatry, Uluslararası, Scopus, 2022, cilt 60, ss 23-27
DOI: 10.29399/npa.28081
Özet
Introduction: Fingolimod is the first oral immunomodulatory treatment used as secondary care therapy in the treatment of multiple sclerosis for the last 10 years. The objective of our study is to reveal the experiences of the first generic fingolimod active ingredient treatment in different centers across Turkey. Method: month following the treatment. The data were analyzed using the IBM SPSS 20.00. P value of <0.05 was considered to be statistically significant. Results: A total of 508 multiple sclerosis patients, 331 of whom were women, were included in the study. Upon comparing the Expanded Disability Status values before and after the treatment, a significant decrease was observed, especially at month 6 and thereafter. Since bradycardia occurred in 11 of the patients (2.3%), the first dose had to be longer than 6 hours. During the observation of the first dose, no issues that could prevent the use of the drug occured. Side effects were seen in 49 (10.3%) patients during the course of fingolimod treatment. Respectively, the most frequent side effects were bradycardia, hypotension, headache, dizziness and tachycardia. Conclusion: The observed results regarding efficacy and safety were similar to clinical trial data in the literature and real life data in terms of the first equivalent with fingolimod active ingredient.